2. Academic Validation
  3. Itolizumab in Psoriasis

Itolizumab in Psoriasis

  • Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. doi: 10.4103/ijd.IJD_467_16.
Ankita Srivastava 1
Affiliations

Affiliation

  • 1 Department of Skin and VD, JNU Institute for Medical Sciences and Research Centre, Jaipur, Rajasthan, India.
PMID: 28794555 DOI: 10.4103/ijd.IJD_467_16
Abstract

A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with infusion reactions as the most common adverse effect. However, its advantages and disadvantages over other biologicals and immunosuppressants need to be established. Also, its utility in treating other immune-mediated disorders is being explored.

Keywords

Anti-CD6 monoclonal antibody; itolizumab; psoriasis; treatment.

Figures
Products